Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus thuringiensis
- Development stage
- Unknown
- Lead developer
- BASF
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Topical
01
Overview
Bacillus thuringiensis is a gram-positive, soil-dwelling bacterium widely used as a biological pesticide. It produces proteinaceous crystal toxins (Cry and Cyt proteins) during sporulation that are toxic to specific insect larvae when ingested. These toxins bind to receptors in the gut of susceptible insects (mainly Lepidoptera, Diptera, Coleoptera), causing cell lysis and death by starvation. Different subspecies or strains target different insect groups; for example, B. thuringiensis kurstaki targets caterpillars while B. thuringiensis israelensis targets mosquito larvae[1][4][5][6]. Bt is considered non-toxic to humans and most non-target organisms due to the specificity of its mode of action[2][4]. It is used in agriculture as a microbial insecticide and has also been incorporated into genetically modified crops for pest resistance[1].
- Other names
- BtBacillus thuringiensis kurstakiBacillus thuringiensis israelensisBacillus thuringiensis aizawaiBacillus thuringiensis tenebrionis
02
Targets
DFFB (Multifunctional protein CAD)ABC family (ATP-binding cassette transporter family)ANPEP (Aminopeptidase N)
Beyond the preview
Go deeper on bacillus thuringiensis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus thuringiensis.